177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.

Trial Details

NCT ID
NCT06305962
Phase
EARLY_PHASE1
Sponsor
Radiopharm Theranostics, Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Locations (sample)
  • Gosford, New South Wales, Australia|-33.4244,151.34399
  • Kingswood, New South Wales, Australia|-33.75614,150.72346
  • Wollongong, New South Wales, Australia|-34.424,150.89345
  • Southport, Queensland, Australia|-27.96724,153.39796
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Adult participants ≥ 18 years of age.
  • Participants with a documented history of histopathologically confirmed relapsed/refractory locally advanced, inoperable or metastatic NSCLC, SCLC,…
  • Participants with PD-L1 positive NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC, endometrial cancer or any cancer that is known to be MMR deficient o…
  • If the participant tumour's PD-L1 expression status is unknown, PD-L1 positivity will be determined by IHC testing using a validated test (tumour t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →